SpringWorks Therapeutics, Inc.
NASDAQ:SWTX
33.99 (USD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 5.447 | 6.147 | 0 | 35 | 0 | 0 | 0 |
| Cost of Revenue
| 0.422 | 1.896 | 0.49 | 0.349 | 0.192 | 0.017 | 0.003 |
| Gross Profit
| 5.025 | 4.251 | -0.49 | 34.651 | -0.192 | -0.017 | -0.003 |
| Gross Profit Ratio
| 0.923 | 0.692 | 0 | 0.99 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 150.487 | 146.122 | 101.676 | 51.859 | 42.545 | 9.898 | 2.799 |
| General & Administrative Expenses
| 197.551 | 134.552 | 71.792 | 29.465 | 16.694 | 8.593 | 5.583 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | -3.725 |
| SG&A
| 197.551 | 134.552 | 71.792 | 29.465 | 16.694 | 8.593 | 1.858 |
| Other Expenses
| 0 | -0.138 | -0.152 | 0.025 | 0 | 0 | 0 |
| Operating Expenses
| 348.038 | 280.674 | 173.468 | 81.324 | 59.239 | 18.491 | 4.657 |
| Operating Income
| -343.013 | -280.674 | -173.468 | -46.324 | -59.239 | -18.491 | -4.66 |
| Operating Income Ratio
| -62.973 | -45.66 | 0 | -1.324 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -5.038 | 3.257 | -0.442 | 0.75 | 0.933 | 0.678 | 0.021 |
| Income Before Tax
| -325.104 | -277.417 | -173.91 | -45.574 | -58.306 | -17.813 | -4.639 |
| Income Before Tax Ratio
| -59.685 | -45.13 | 0 | -1.302 | 0 | 0 | 0 |
| Income Tax Expense
| -22.947 | -3.257 | -0.698 | -1.33 | -3.547 | 0.678 | -0 |
| Net Income
| -325.104 | -274.16 | -173.212 | -44.244 | -54.759 | -17.813 | -4.639 |
| Net Income Ratio
| -59.685 | -44.601 | 0 | -1.264 | 0 | 0 | 0 |
| EPS
| -5.15 | -5.14 | -3.57 | -1.02 | -1.27 | -0.8 | -0.11 |
| EPS Diluted
| -5.15 | -5.14 | -3.57 | -1.02 | -1.27 | -0.8 | -0.11 |
| EBITDA
| -341.346 | -280.674 | -172.978 | -45.975 | -59.047 | -18.474 | -4.657 |
| EBITDA Ratio
| -62.667 | -45.66 | 0 | -1.314 | 0 | 0 | 0 |